Minimal residual disease by flow cytometry and allelic-specific oligonucleotide real-time quantitative polymerase chain reaction in patients with myeloma receiving lenalidomide maintenance: A pooled analysis.

Manuela GambellaPaola OmedéStefano SpadaVittorio Emanuele MuccioMilena GilestroElona SaraciSara GrammaticoAlessandra LaroccaConcetta ConticelloAnnalisa BernardiniBarbara GamberiRossella TroiaAnna Marina LiberatiMassimo OffidaniAlberto RocciAntonio PalumboMichele CavoPieter SonneveldMario BoccadoroStefania Oliva

Published in: Cancer (2018)

MRD status is a stronger predictor of PFS than standard risk factors, and lenalidomide maintenance further increases the rate of negative MRD results.

Keyphrases

flow cytometry
multiple myeloma
newly diagnosed
risk factors
stem cell transplantation
chronic lymphocytic leukemia
high resolution
high dose
low dose